US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PagerDuty, Inc.

16.99

-1.3200-7.21%

Post-market: 16.990.00000.00%19:11 EDT

Volume:1.83M

Turnover:31.19M

Market Cap:1.55B

PE:-28.70

High:17.66

Open:17.49

Low:16.87

Close:18.31

Loading ...

Overview Company News Filings

PagerDuty Announces Fourth Quarter and Full Year Fiscal 2025 Financial Results

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Press Release: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Press Release: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Investing in PagerDuty (NYSE:PD) five years ago would have delivered you a 31% gain

Simply Wall St.

PagerDuty Appoints Allison Corley as Chief Customer Officer

THOMSON REUTERS

PagerDuty Appoints Allison Corley as Chief Customer Officer

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Lifeward (LFWD) Reports Q4 Loss, Tops Revenue Estimates

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Box (BOX) Beats Q4 Earnings and Revenue Estimates

Supernus to Participate in Two Upcoming Investor Conferences

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

ACCESS Newswire

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

A Tribute to Richard Parsons: He Lived His Best CEO Life and Much More Than Too -- Barrons.com

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PD/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":16.99,"timestamp":1743710400000,"preClose":18.31,"halted":0,"volume":1827950,"hourTrading":{"tag":"盘后","latestPrice":16.99,"preClose":16.99,"latestTime":"19:11 EDT","volume":80383,"amount":1365687.91,"timestamp":1743721896205},"delay":0,"floatShares":81906729,"shares":91084454,"eps":-0.591956,"marketStatus":"Closed","change":-1.32,"latestTime":"04-03 16:00:00 EDT","open":17.49,"high":17.66,"low":16.87,"amount":31193866.212750003,"amplitude":0.043146,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.591956,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743753600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":18.31,"preHourTrading":{"tag":"盘前","latestPrice":17.19,"preClose":18.31,"latestTime":"09:28 EDT","volume":1072,"amount":18386.770336,"timestamp":1743686910123},"postHourTrading":{"tag":"盘后","latestPrice":16.99,"preClose":16.99,"latestTime":"19:11 EDT","volume":80383,"amount":1365687.91,"timestamp":1743721896205},"volumeRatio":1.971865,"impliedVol":0.471,"impliedVolPercentile":0.4024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","floatShares":81906729,"roa":"-4.03%","roe":"-26.63%","lyrEps":-0.591956,"volumeRatio":1.971865,"shares":91084454,"dividePrice":0,"high":17.66,"amplitude":0.043146,"preClose":18.31,"low":16.87,"week52Low":15.49,"pbRate":"11.92","psRate":"3.31","week52High":23.4,"institutionHeld":0,"latestPrice":16.99,"eps":-0.591956,"divideRate":0,"volume":1827950,"delay":0,"ttmEps":-0.591956,"open":17.49,"prevYearClose":18.26,"prevWeekClose":18.77,"prevMonthClose":18.27,"prevQuarterClose":18.27,"fiveDayClose":19.02,"twentyDayClose":17.27,"sixtyDayClose":17.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PD\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519039867","title":"PagerDuty Announces Fourth Quarter and Full Year Fiscal 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2519039867","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519039867?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:05","pubTimestamp":1741896300,"startTime":"0","endTime":"0","summary":"Fourth quarter revenue increased 9.3% year over year to $121 million. Fourth quarter loss from operations was $12 million; non-GAAP operating income was $22 million. Introduced Agentic Artificial Intelligence  offerings in the PagerDuty Operations Cloud. SAN FRANCISCO, March 13, 2025----PagerDuty, Inc. , a leader in digital operations management, today announced financial results for the fourth quarter and full year of fiscal 2025, ended January 31, 2025.PagerDuty also announced today that its Board of Directors has authorized a new share repurchase program for up to $150 million of common stock.\"PagerDuty continues to demonstrate strong business fundamentals and sustainable free cash flow generation,\" said Howard Wilson, Chief Financial Officer, PagerDuty. \"This second share repurchase program underscores our ongoing commitment to managing share count growth while reflecting our Board and management team’s continued confidence in our long-term strategy and market opportunity.\". The se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pagerduty-announces-fourth-quarter-full-200500644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169589451.USD","LU1169590202.USD","PD","BK4023"],"gpt_icon":0},{"id":"2519558835","title":"TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519558835","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519558835?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:47","pubTimestamp":1741866420,"startTime":"0","endTime":"0","summary":"Clinical trial Safety Review Committee  approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3. No significant safety or dose limiting toxicities reported in Cohorts 1, 2, or 3. Patients currently being evaluated for Cohort 4 eligibility. \"SRC approval to open the fourth cohort and expand enrollment in Cohort 3 is an important advancement for the clinical trial. It will provide an opportunity to obtain additional safety and PK/PD data, inform the dose expansion stage of the clinical trial and may allow us to obtain initial evidence of clinical activity\" commented Sue Duggan, TransCode's Senior Vice President of Operations. Duggan added, \"Enrollment into the study continues based on the cumulative safety data review. Eligible subjects may now be screened and scheduled in Cohort 4 for treatment with the next dose level of TTX-MC138","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-safety-review-114700704.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-safety-review-114700704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4023","BK4139","PK","RNAZ","BK4080","PD","LU1169589451.USD","LU1169590202.USD","BK4218","BK4181","SRC","BK4539","LENZ"],"gpt_icon":0},{"id":"2519887682","title":"Press Release: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887682?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"-- Landmark exclusive option and license deal with Takeda for ACI-24.060. with $100 million upfront and additional potential milestones of up to. about $2.1 billion plus royalties on sales upon commercialization. -- ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and. tolerability data in Down syndrome  cohort; further interim results. in Alzheimer's disease  and DS expected in 2025. -- Enrollment progress in JNJ-2056  ReTain Phase 2b trial in. preclinical AD patients triggered second milestone payment of CHF 24.6. -- ACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety. and immunogenicity results in Parkinson's disease ; further interim. \"The ability to innovate is key to our future success. Driven by our two drug discovery platforms, in 2024, we advanced multiple early-stage asse","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACIU","IE00B42XCP33.USD","IE00B2B36J28.USD","IE00BVYPNV92.GBP","SG9999002224.SGD","LU1032466523.USD","LU2505996509.AUD","LU1059921491.USD","LU1221951129.SGD","AAIC","IE000M9KFDE8.USD","LU0640476718.USD","LU0912757837.SGD","PSP","LU0114720955.EUR","JNJ","PD","LU1169589451.USD","LU0792757196.USD","LU1162221912.USD","ACI","BK4604","PET","BK4581","R","IE0009355771.USD","LU1244550577.SGD","LU1244550494.USD","03160","LU0098860793.USD","IE00BSNM7G36.USD","BK4555","TM","AC","BK4532","ARIA","LU0345769128.USD","BK4007","LU0203345920.USD","IE00BDGV0183.EUR","LU2430703095.HKD","IE00B4R5TH58.HKD","BK4592","LU0320765646.SGD","LU1778281490.HKD","LU0234572021.USD","CBD","LU1506573853.SGD","LU0234570918.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2519887161","title":"Press Release: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887161?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates. -- Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer's Disease ; plans to initiate Phase 2 clinical trial in Q3 2025 --. -- On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 --. WATERTOWN, Mass., March 13, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided updates on recent progress.Final analysis from IGNITE Phase 2 clinical trial planned for second quarter of 2025:. -- The Company plans to report the final analysis from the IGNITE Phase 2. clinical trial, including all patients at 12 months dosed with either 20. iluzanebart in ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIGL","BK4023","BK4588","VG","PD","LU1169589451.USD","BK4604","BK4181","BK4139","TM","03160","BK4555","LU1169590202.USD","BK4218","BK4099","BK4213","BK4585","CSF","PK"],"gpt_icon":0},{"id":"2518748268","title":"Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748268","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518748268?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March  11, 2025  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040492/0/en/Annovis-Joins-Experts-at-Drug-Development-Summit-to-Redefine-Parkinson-s-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","LU1169590202.USD","PD","BK4023","SMMF","BK4139","ANVS","BK4211"],"gpt_icon":0},{"id":"2518470497","title":"Investing in PagerDuty (NYSE:PD) five years ago would have delivered you a 31% gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2518470497","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518470497?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:55","pubTimestamp":1741694148,"startTime":"0","endTime":"0","summary":"It hasn't been the best quarter for PagerDuty, Inc.  shareholders, since the share price has fallen 17% in that time. On the bright side the share price is up over the last half decade. Unfortunately its return of 31% is below the market return of 153%. While the long term returns are impressive, we do have some sympathy for those who bought more recently, given the 29% drop, in the last year.So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.Given that PagerDuty didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.Please note, the market returns quoted in this article reflect the market weigh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investing-pagerduty-nyse-pd-five-115548241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","PD","NYSE","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2518200315","title":"PagerDuty Appoints Allison Corley as Chief Customer Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2518200315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518200315?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:05","pubTimestamp":1741637101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUAC9LMP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1169589451.USD","LU1169590202.USD","PD","BK4023"],"gpt_icon":0},{"id":"2518788615","title":"PagerDuty Appoints Allison Corley as Chief Customer Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2518788615","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518788615?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:05","pubTimestamp":1741637100,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, March 10, 2025----PagerDuty, Inc. , a global leader in digital operations management, announced today the appointment of Allison Corley as Chief Customer Officer. Corley will be responsible for driving the company’s customer-centric strategy and ensuring exceptional customer experiences across the entire customer journey. She will lead PagerDuty’s Customer Success Group, including professional services, global customer success management, education services, customer support, renewal management and customer success engineering.\"We are thrilled to welcome Allison to PagerDuty. She brings a proven ability to drive customer adoption, retention, and lifetime customer value at a time when our customers are accelerating their digital initiatives,\" said Jennifer Tejada, Chairperson and CEO at PagerDuty. \"Allison’s arrival strengthens our distinguished leadership bench and will contribute significantly to our growth strategy.\". The PagerDuty Operations Cloud is the platform for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pagerduty-appoints-allison-corley-chief-200500580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169590202.USD","LU1169589451.USD","BK4023","NYSE","PD"],"gpt_icon":0},{"id":"2518225005","title":"Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2518225005","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518225005?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:19","pubTimestamp":1741609140,"startTime":"0","endTime":"0","summary":"SANTA CLARA, Calif., March 10, 2025----Agilent Technologies Inc.  today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer  and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution.When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union:  resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be eligible for treatment with Bristol Myers Squibb’s OPDIVO  in combination with platinum based chemotherapy; and  patients 12 years of age and older with tumor cell PD-L1 expression < 1% that have previously untreated advanced  melanoma may be eligible fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agilent-pd-l1-ihc-28-121900529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BN0W2V16.EUR","LU0985481810.HKD","LU1430594728.SGD","LU1868836757.USD","LU0237698245.USD","IE0009355771.USD","LU0347712357.USD","LU1868836914.USD","LU1323610961.USD","BK4534","LU1032466523.USD","PD","LU0306807586.USD","BMY","IE00BN0W2T93.GBP","LU1074936037.SGD","BK4585","IE00BSNM7G36.USD","LU0061475181.USD","LU0456855351.SGD","LU2413666426.HKD","LU1718418525.SGD","LU0321505868.SGD","LU1670710661.SGD","LU0225771236.USD","LU2125154935.USD","BK4559","BK4588","LU1670710588.SGD","LU1670711123.USD","LU1868836591.USD","IE00BFTCPJ56.SGD","LU1093756325.SGD","LU1169590202.USD","BK4162","A","LU1989771016.USD","IHC","IE00BN0W2W23.USD","LU2242646821.SGD","LU1670711040.USD","IE00BFXG1179.USD","LU2092937221.SGD","IE0002141913.USD","LU1291159041.SGD","BK4581","LU1165135440.EUR","IE00BJT1NW94.SGD","BK4121"],"gpt_icon":0},{"id":"2518423852","title":"Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518423852","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518423852?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:07","pubTimestamp":1741604820,"startTime":"0","endTime":"0","summary":"Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039587/0/en/Design-Therapeutics-Highlights-Progress-Across-Lead-GeneTAC-Programs-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HD","LU1035775433.USD","LU0079474960.USD","LU1169590202.USD","LU1162221912.USD","PD","LU1929549753.HKD","BK4533","LU0820562030.AUD","LU0868494617.USD","IE00BKVL7J92.USD","LU1989772840.SGD","LU0942090050.USD","IE00BZ1G4Q59.USD","LU0234572021.USD","LU1093756325.SGD","BK4097","BK4539","BK4023","LU1674673691.USD","LU0823434740.USD","BK4585","LU2756315664.SGD","FA","LU1496350171.SGD","BK4505","LU0943347566.SGD","BK4535","BK4588","LU1914381329.SGD","LU0320765646.SGD","LU0823411888.USD","BK4181","BK4566","BK4534","PK","LU0820561818.USD","PRGS","SG9999001440.SGD","LU1551013342.USD","BK4218","BK4504","IE00B1XK9C88.USD","LU1778281490.HKD","LU2756315318.SGD","LU1093756168.USD","IE00BWXC8680.SGD","DSGN","LENZ","LU0868494708.USD"],"gpt_icon":0},{"id":"2517458215","title":"Lifeward (LFWD) Reports Q4 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517458215","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517458215?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:25","pubTimestamp":1741357503,"startTime":"0","endTime":"0","summary":"Lifeward  came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -90%. A quarter ago, it was expected that this maker of wearable robotic exoskeletons that help paralyzed patients walk would post a loss of $0.27 per share when it actually produced a loss of $0.45, delivering a surprise of -66.67%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Lifeward , which belongs to the Zacks Internet - Software industry, posted revenues of $7.55 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.36%. This compares to year-ago revenues of $6.88 million. The company has topped consensus revenue estimates just once over the last four quarters.Investors should be mindful of the fact that the outlook for the indust","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lifeward-lfwd-reports-q4-loss-142503441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LFWD","PD"],"gpt_icon":0},{"id":"2517480505","title":"InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480505?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"JENA, Germany, March  07, 2025  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038913/0/en/InflaRx-Showcases-Vilobelimab-s-Role-in-Immuno-Dermatology-at-the-2025-AAD-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836914.USD","BK4558","LU1162221912.USD","SG9999015358.SGD","LU0868494617.USD","BK4559","ARDS","SG9999015341.SGD","LU2552382215.SGD","BK4018","BK4568","PK","LU1430594728.SGD","PD","SG9999002232.USD","IE00BWXC8680.SGD","PG","LU1868836591.USD","SG9999014542.SGD","SG9999002224.SGD","BK4181","SG9999014575.USD","USA","LU0689626769.HKD","BK4504","BK4567","LU1929549753.HKD","LU2129689514.USD","SG9999001440.SGD","LU1066051498.USD","LU2129689431.USD","BK4139","IE00B3T34201.USD","BK4535","IE00BBT3K403.USD","LU1066053197.SGD","BNTX","LU0234572021.USD","LU1868837300.USD","LU1169589451.USD","LU0061475181.USD","LU0234570918.USD","BK4533","LU1585245621.USD","LU1868837136.USD","IE00BLSP4239.USD","SG9999014567.USD","BK4581","BK4534","LU0094547139.USD"],"gpt_icon":0},{"id":"2517154760","title":"Gain Therapeutics Announces Oral Presentation at AD/PD 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154760","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154760?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:55","pubTimestamp":1741265700,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., March  06, 2025  (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038110/0/en/Gain-Therapeutics-Announces-Oral-Presentation-at-AD-PD-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GT","BK4588","BK4585","LU1169589451.USD","GANX","BK4119","PD","LU1169590202.USD","BK4139","BK4023","LENZ"],"gpt_icon":0},{"id":"2517921134","title":"ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921134","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921134?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:10","pubTimestamp":1741209000,"startTime":"0","endTime":"0","summary":"neffy1 mgis the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March  05, 2025  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037769/0/en/ARS-Pharmaceuticals-Announces-FDA-Approval-of-neffy-1-mg-epinephrine-nasal-spray-for-Type-I-Allergic-Reactions-Including-Anaphylaxis-in-Pediatric-Patients-Weighing-15-to-30-Kilogra.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","LU1169590202.USD","PD","BK4023","LU1169589451.USD","BK4181","PK"],"gpt_icon":0},{"id":"2517393810","title":"Box (BOX) Beats Q4 Earnings and Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517393810","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517393810?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:30","pubTimestamp":1741127402,"startTime":"0","endTime":"0","summary":"Box  came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.44%. A quarter ago, it was expected that this online storage provider would post earnings of $0.42 per share when it actually produced earnings of $0.45, delivering a surprise of 7.14%.Box , which belongs to the Zacks Internet - Software industry, posted revenues of $279.52 million for the quarter ended January 2025, surpassing the Zacks Consensus Estimate by 0.19%. This compares to year-ago revenues of $262.88 million. The company has topped consensus revenue estimates four times over the last four quarters.Box shares have added about 3.7% since the beginning of the year versus the S&P 500's decline of -0.5%.While Box has outperformed the market so far this year, the question that comes to investors' minds i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/box-box-beats-q4-earnings-223002771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","BOX"],"gpt_icon":0},{"id":"2517981626","title":"Supernus to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2517981626","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517981626?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:30","pubTimestamp":1741123800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., March  04, 2025  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036999/19871/en/Supernus-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","LU1169590202.USD","PD","BK4023","LU1169589451.USD","CNS","ADHD"],"gpt_icon":0},{"id":"2516678211","title":"Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2516678211","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516678211?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc.  , a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1  and Vascular Endothelial Growth Factor  receptors. Using its proprietary EpiClick Technology, a versatile multispecific antibody engineering platform, HS1940 represents a key expansion of Tharimmune's product pipeline and underscores the Company's commitment to addressing unmet needs.The Company has generated positive target engagement data showing that the biparatopic format expands therapeutic versatility compared with monospecific antibodies, which are limited to targeting a single epitope on a single receptor. As illustrated, the biparatopic antibody constructs effectively achieve target engagement on both PD-1 and VEGF. By engaging two distinct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-positive-target-engagement-120000409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169589451.USD","LU1169590202.USD","BK4023","PD","BK4139","THAR","PBC"],"gpt_icon":0},{"id":"2516684183","title":"Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684183","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684183?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:05","pubTimestamp":1740999900,"startTime":"0","endTime":"0","summary":"Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035381/0/en/Apogee-Therapeutics-Provides-Pipeline-Progress-and-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4218","LU2065732104.USD","LU1169589451.USD","BK4023","PK","PD","PRGS","TSLP","APGE","BK4181","BK4097","LU1169590202.USD"],"gpt_icon":0},{"id":"2516307126","title":"A Tribute to Richard Parsons: He Lived His Best CEO Life and Much More Than Too -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2516307126","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516307126?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:43","pubTimestamp":1740778980,"startTime":"0","endTime":"0","summary":"Miles Davis, Duke Ellington, Martin Luther King Jr., and all manner of other luminaries have graced Harlem's famed Apollo Theater stage over the years. Thursday, a different sort of legendary figure, Richard Dean Parsons, was honored there with a Celebration of Life ceremony, with a diverse crowd of boldfaced names and ordinary folks alike in attendance.Parsons also served as co-chair of the advisory board of the Smithsonian National Museum of African American History and Culture and was chair of the Jazz Foundation of America and chair of the Rockefeller Foundation, the latter of which speaks to a longstanding relationship with that prominent American family. One of Parson's grandfathers had been head groundskeeper at John D. Rockefeller's estate. In Parsons' final year at the University of Albany Law School , he received an internship with then New York Gov. Nelson R","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0648001328.SGD","LU0130517989.USD","LAZ","BK4585","BK4558","LU0320765646.SGD","EL","BK4504","LU2236285917.USD","LU2404859741.USD","BK4548","LU1169589451.USD","LU0690374615.EUR","IE00BSNM7G36.USD","PD","LU0052756011.USD","LU0980610538.SGD","LU2552382058.USD","BK4207","LU2417539215.USD","LU0128525689.USD","LU1201861249.SGD","LU1162221912.USD","LU2360032135.SGD","LU0162691827.USD","LU1267930227.SGD","LU1366192091.USD","BK4566","LU0072461881.USD","LU2125154935.USD","BK4588","LU2456880835.USD","LU2125154778.USD","BK4534","LU0170899867.USD","LU2462157665.USD","LU0106831901.USD","LU0130102774.USD","LU0310800965.SGD","BK4023","BK4533","LU2552382132.HKD","BK4183","LU0477156953.USD","LU1791807156.HKD","LU0098860793.USD","LU2552382215.SGD","LU1169590202.USD","LU1668664300.SGD","LU0690374961.EUR"],"gpt_icon":0},{"id":"2514358922","title":"Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358922","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358922?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:15","pubTimestamp":1740690900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025  -- Alumis Inc.  , a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the Company will give two data presentations on A-005, a potent, selective, central nervous system  penetrant tyrosine kinase 2  inhibitor, on Friday, February 28, 2025, at the 10th Annual Americas Committee for Treatment and Research in Multiple Sclerosis  Forum 2025.“These data demonstrate that A-005 potently inhibits TYK2-specific signaling in immune cells and CNS resident cells, targeting pro-inflammatory cytokine pathways implicated in the pathology of neuroinflammatory diseases,” said Jrn Drappa, M.D., Alumis’ Chief Medical Officer. “As the first reported allosteric TYK2 inhibitor with demonstrated ability to cross the blood-brain barrier, A-005 represents a novel approach to potentially treating a bro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-presents-additional-phase-1-211500176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","BK4181","BK4218","BK4007","FET","PK","LU1169589451.USD","BK4179","BK4135","LU1169590202.USD","BK4023","CNS","ALMS"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"PD","fiscalQuarterEnding":"2025/01","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-11-26","symbol":"PD","fiscalQuarterEnding":"2024/10","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2024-09-03","symbol":"PD","fiscalQuarterEnding":"2024/07","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-05-30","symbol":"PD","fiscalQuarterEnding":"2024/04","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1717041600000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2024-03-14","symbol":"PD","fiscalQuarterEnding":"2024/01","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710388800000,"reportTimeType":"post","actualEps":-0.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0769,"buy":0.3077,"hold":0.4615,"sell":0.1538,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.4615,"analysts":13,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PD","date":"2025-04-02","current":-30.740585,"percent":0.358444,"low":-81.051795,"twenty":-43.157994,"median":-25.114351,"eighty":-20.118618,"high":-13.794086,"avg":-30.688829,"sd":13.440507,"marketCap":1674132264},"quantilePoints":[{"date":"2020-04-03","current":-23.359252,"twenty":-78.151123,"median":-44.821428,"eighty":-37.756742,"marketCap":1175881369},{"date":"2020-04-09","current":-28.429956,"twenty":-77.931632,"median":-44.243832,"eighty":-37.508627,"marketCap":1431135564},{"date":"2020-04-17","current":-32.325741,"twenty":-77.435709,"median":-43.781756,"eighty":-36.980797,"marketCap":1627245494},{"date":"2020-04-24","current":-33.176012,"twenty":-77.284281,"median":-43.600226,"eighty":-36.837683,"marketCap":1670047265},{"date":"2020-05-01","current":-32.047471,"twenty":-76.727947,"median":-43.369188,"eighty":-36.303053,"marketCap":1613237642},{"date":"2020-05-08","current":-38.278643,"twenty":-76.441551,"median":-43.006127,"eighty":-35.678665,"marketCap":1926908589},{"date":"2020-05-15","current":-40.070276,"twenty":-76.181489,"median":-42.907111,"eighty":-35.799269,"marketCap":2017097635},{"date":"2020-05-22","current":-43.435432,"twenty":-76.082732,"median":-42.504512,"eighty":-36.303053,"marketCap":2186496193},{"date":"2020-05-29","current":-41.363368,"twenty":-75.845714,"median":-42.329073,"eighty":-36.388531,"marketCap":2082190599},{"date":"2020-06-05","current":-41.572682,"twenty":-75.735317,"median":-42.449993,"eighty":-36.532943,"marketCap":2067575752},{"date":"2020-06-12","current":-39.198908,"twenty":-75.187331,"median":-42.329073,"eighty":-36.817602,"marketCap":1949518515},{"date":"2020-06-19","current":-48.393323,"twenty":-74.002242,"median":-42.496137,"eighty":-36.834452,"marketCap":2406793548},{"date":"2020-06-26","current":-46.067026,"twenty":-73.969323,"median":-42.888728,"eighty":-36.850607,"marketCap":2291097455},{"date":"2020-07-02","current":-47.49129,"twenty":-73.92982,"median":-42.964871,"eighty":-36.863809,"marketCap":2361931798},{"date":"2020-07-10","current":-44.658587,"twenty":-72.98504,"median":-43.055636,"eighty":-36.906716,"marketCap":2221050161},{"date":"2020-07-17","current":-40.765599,"twenty":-72.685476,"median":-42.964871,"eighty":-36.931288,"marketCap":2027436292},{"date":"2020-07-24","current":-42.807044,"twenty":-72.640646,"median":-42.989625,"eighty":-37.118318,"marketCap":2128965516},{"date":"2020-07-31","current":-48.235072,"twenty":-72.530247,"median":-43.175427,"eighty":-37.208604,"marketCap":2398923066},{"date":"2020-08-07","current":-47.238087,"twenty":-72.318638,"median":-43.360924,"eighty":-37.407321,"marketCap":2349339026},{"date":"2020-08-14","current":-46.177802,"twenty":-72.098738,"median":-43.468321,"eighty":-37.467623,"marketCap":2296606793},{"date":"2020-08-21","current":-45.95625,"twenty":-71.69039,"median":-43.550826,"eighty":-37.518859,"marketCap":2285588118},{"date":"2020-08-28","current":-48.583225,"twenty":-71.41486,"median":-43.699242,"eighty":-37.630539,"marketCap":2416238127},{"date":"2020-09-04","current":-38.528058,"twenty":-71.368789,"median":-43.748751,"eighty":-37.658486,"marketCap":1997756875},{"date":"2020-09-11","current":-36.766338,"twenty":-71.24954,"median":-43.637964,"eighty":-37.464273,"marketCap":1906408152},{"date":"2020-09-18","current":-38.03784,"twenty":-70.931543,"median":-43.525964,"eighty":-37.424178,"marketCap":1972338100},{"date":"2020-09-25","current":-40.596165,"twenty":-70.750862,"median":-43.369188,"eighty":-37.464273,"marketCap":2104992334},{"date":"2020-10-02","current":-42.378825,"twenty":-69.760733,"median":-43.304333,"eighty":-37.506887,"marketCap":2197426830},{"date":"2020-10-09","current":-45.308378,"twenty":-68.893466,"median":-43.360924,"eighty":-37.540906,"marketCap":2349330024},{"date":"2020-10-16","current":-46.719472,"twenty":-68.681421,"median":-43.459295,"eighty":-37.566006,"marketCap":2422498055},{"date":"2020-10-23","current":-44.664183,"twenty":-67.026675,"median":-43.550718,"eighty":-37.624584,"marketCap":2315927228},{"date":"2020-10-30","current":-41.565912,"twenty":-65.321463,"median":-43.550772,"eighty":-37.657731,"marketCap":2155275682},{"date":"2020-11-06","current":-46.121291,"twenty":-64.742086,"median":-43.550826,"eighty":-37.676934,"marketCap":2391481172},{"date":"2020-11-13","current":-46.35136,"twenty":-63.787431,"median":-43.643849,"eighty":-37.728931,"marketCap":2403410742},{"date":"2020-11-20","current":-47.79313,"twenty":-62.855819,"median":-43.781756,"eighty":-37.757248,"marketCap":2478169382},{"date":"2020-11-27","current":-52.440537,"twenty":-62.329113,"median":-43.973974,"eighty":-37.811067,"marketCap":2719146700},{"date":"2020-12-04","current":-58.503982,"twenty":-61.897872,"median":-44.116471,"eighty":-37.910083,"marketCap":3346135266},{"date":"2020-12-11","current":-61.956348,"twenty":-61.897872,"median":-44.23472,"eighty":-37.979009,"marketCap":3543593297},{"date":"2020-12-18","current":-64.76408,"twenty":-63.261641,"median":-44.342085,"eighty":-38.134161,"marketCap":3704181571},{"date":"2020-12-24","current":-65.981719,"twenty":-64.468982,"median":-44.366057,"eighty":-38.286785,"marketCap":3773824445},{"date":"2020-12-31","current":-59.735947,"twenty":-64.377301,"median":-44.622066,"eighty":-38.319351,"marketCap":3416597468},{"date":"2021-01-08","current":-63.775644,"twenty":-64.248374,"median":-44.664183,"eighty":-38.342002,"marketCap":3647647944},{"date":"2021-01-15","current":-65.265461,"twenty":-64.491902,"median":-44.85652,"eighty":-38.342002,"marketCap":3732858049},{"date":"2021-01-22","current":-70.007091,"twenty":-64.924465,"median":-44.940871,"eighty":-38.368803,"marketCap":4004055593},{"date":"2021-01-29","current":-69.806539,"twenty":-66.010369,"median":-45.124322,"eighty":-38.447577,"marketCap":3992585002},{"date":"2021-02-05","current":-78.774094,"twenty":-67.606194,"median":-45.279297,"eighty":-38.515566,"marketCap":4505484287},{"date":"2021-02-12","current":-81.051795,"twenty":-68.875403,"median":-45.308378,"eighty":-38.533013,"marketCap":4635757427},{"date":"2021-02-19","current":-74.533844,"twenty":-69.256452,"median":-45.492434,"eighty":-38.599807,"marketCap":4262963219},{"date":"2021-02-26","current":-64.090797,"twenty":-69.256452,"median":-45.616009,"eighty":-38.656949,"marketCap":3665673158},{"date":"2021-03-05","current":-53.862628,"twenty":-69.159583,"median":-45.671397,"eighty":-38.66724,"marketCap":3080673016},{"date":"2021-03-12","current":-60.509506,"twenty":-69.072496,"median":-45.726784,"eighty":-38.673459,"marketCap":3460841176},{"date":"2021-03-19","current":-49.639711,"twenty":-68.918379,"median":-45.797998,"eighty":-38.687063,"marketCap":3420324980},{"date":"2021-03-26","current":-46.372989,"twenty":-68.782324,"median":-45.852876,"eighty":-38.706425,"marketCap":3195238028},{"date":"2021-04-01","current":-49.627656,"twenty":-68.703922,"median":-45.852876,"eighty":-38.74149,"marketCap":3419494401},{"date":"2021-04-09","current":-50.688437,"twenty":-68.634603,"median":-45.95625,"eighty":-38.792193,"marketCap":3492585367},{"date":"2021-04-16","current":-50.965686,"twenty":-68.620415,"median":-46.098464,"eighty":-38.810779,"marketCap":3511688688},{"date":"2021-04-23","current":-50.965686,"twenty":-68.551655,"median":-46.177802,"eighty":-38.849388,"marketCap":3511688688},{"date":"2021-04-30","current":-51.182664,"twenty":-68.073194,"median":-46.296231,"eighty":-38.932876,"marketCap":3526639113},{"date":"2021-05-07","current":-45.52431,"twenty":-67.425697,"median":-46.35136,"eighty":-39.005886,"marketCap":3136761501},{"date":"2021-05-14","current":-42.286432,"twenty":-67.150653,"median":-46.187891,"eighty":-39.046881,"marketCap":2913662055},{"date":"2021-05-21","current":-44.081211,"twenty":-66.824039,"median":-46.121291,"eighty":-39.054259,"marketCap":3037327665},{"date":"2021-05-28","current":-49.295769,"twenty":-66.574781,"median":-46.172553,"eighty":-39.081958,"marketCap":3396626399},{"date":"2021-06-04","current":-36.968776,"twenty":-66.216652,"median":-46.172553,"eighty":-39.072116,"marketCap":2957576028},{"date":"2021-06-11","current":-42.279901,"twenty":-66.096321,"median":-46.075636,"eighty":-39.072116,"marketCap":3382476656},{"date":"2021-06-18","current":-45.709132,"twenty":-65.976077,"median":-45.923735,"eighty":-39.125091,"marketCap":3656821944},{"date":"2021-06-25","current":-47.162372,"twenty":-65.815901,"median":-46.067026,"eighty":-39.183405,"marketCap":3773084124},{"date":"2021-07-02","current":-44.130431,"twenty":-65.216755,"median":-46.011638,"eighty":-39.205083,"marketCap":3530522741},{"date":"2021-07-09","current":-45.834591,"twenty":-65.021933,"median":-45.883552,"eighty":-39.229781,"marketCap":3666858967},{"date":"2021-07-16","current":-40.199362,"twenty":-64.900098,"median":-45.829869,"eighty":-39.313533,"marketCap":3216029363},{"date":"2021-07-23","current":-43.325398,"twenty":-64.76408,"median":-45.766347,"eighty":-39.330284,"marketCap":3466118512},{"date":"2021-07-30","current":-42.436726,"twenty":-64.636745,"median":-45.712576,"eighty":-39.369202,"marketCap":3395022935},{"date":"2021-08-06","current":-44.33953,"twenty":-64.491902,"median":-45.685037,"eighty":-39.631794,"marketCap":3547251112},{"date":"2021-08-13","current":-42.269446,"twenty":-64.377301,"median":-45.655572,"eighty":-39.648544,"marketCap":3381640238},{"date":"2021-08-20","current":-40.387552,"twenty":-64.32,"median":-45.516041,"eighty":-39.732297,"marketCap":3231084897},{"date":"2021-08-27","current":-43.743597,"twenty":-64.248374,"median":-45.492434,"eighty":-39.784241,"marketCap":3499575255},{"date":"2021-09-03","current":-42.390054,"twenty":-64.090797,"median":-45.440934,"eighty":-39.784241,"marketCap":4025995391},{"date":"2021-09-10","current":-39.410762,"twenty":-63.838675,"median":-45.357157,"eighty":-39.773852,"marketCap":3743037083},{"date":"2021-09-17","current":-42.488469,"twenty":-63.43184,"median":-45.291593,"eighty":-39.773852,"marketCap":4035342362},{"date":"2021-09-24","current":-41.531159,"twenty":-63.322968,"median":-45.131991,"eighty":-39.806871,"marketCap":3944421825},{"date":"2021-10-01","current":-37.845067,"twenty":-63.294318,"median":-44.969953,"eighty":-39.673042,"marketCap":3594335269},{"date":"2021-10-08","current":-35.304169,"twenty":-63.234694,"median":-44.895964,"eighty":-39.361418,"marketCap":3353013468},{"date":"2021-10-15","current":-36.968279,"twenty":-62.977151,"median":-44.757709,"eighty":-39.195032,"marketCap":3511062253},{"date":"2021-10-22","current":-37.567716,"twenty":-62.673,"median":-44.689179,"eighty":-39.048237,"marketCap":3567993805},{"date":"2021-10-29","current":-37.352992,"twenty":-62.144822,"median":-44.662724,"eighty":-38.884343,"marketCap":3547600413},{"date":"2021-11-05","current":-38.927633,"twenty":-61.970673,"median":-44.622066,"eighty":-38.780249,"marketCap":3697151952},{"date":"2021-11-12","current":-37.684024,"twenty":-61.914834,"median":-44.517265,"eighty":-38.690435,"marketCap":3579040225},{"date":"2021-11-19","current":-34.892615,"twenty":-61.891288,"median":-44.350719,"eighty":-38.663132,"marketCap":3313926135},{"date":"2021-11-26","current":-33.094304,"twenty":-61.87812,"median":-44.340807,"eighty":-38.647574,"marketCap":3143131480},{"date":"2021-12-03","current":-27.717262,"twenty":-61.851785,"median":-44.310434,"eighty":-38.490518,"marketCap":2632446965},{"date":"2021-12-10","current":-29.437491,"twenty":-61.634212,"median":-44.193031,"eighty":-38.342002,"marketCap":2964590848},{"date":"2021-12-17","current":-29.446029,"twenty":-61.446371,"median":-44.130431,"eighty":-38.122419,"marketCap":2965450648},{"date":"2021-12-23","current":-30.863263,"twenty":-61.141525,"median":-44.120926,"eighty":-37.910083,"marketCap":3108177469},{"date":"2021-12-31","current":-29.668005,"twenty":-60.679678,"median":-44.096614,"eighty":-37.767931,"marketCap":2987805451},{"date":"2022-01-07","current":-27.243339,"twenty":-60.561077,"median":-44.020576,"eighty":-37.685906,"marketCap":2743622214},{"date":"2022-01-14","current":-26.466422,"twenty":-60.402519,"median":-43.931787,"eighty":-37.609143,"marketCap":2665380403},{"date":"2022-01-21","current":-25.715117,"twenty":-60.229637,"median":-43.82863,"eighty":-37.535067,"marketCap":2589717991},{"date":"2022-01-28","current":-27.448241,"twenty":-60.179262,"median":-43.748751,"eighty":-37.457573,"marketCap":2764257417},{"date":"2022-02-04","current":-27.106738,"twenty":-60.125395,"median":-43.643849,"eighty":-37.310047,"marketCap":2729865412},{"date":"2022-02-11","current":-28.728874,"twenty":-59.884929,"median":-43.550718,"eighty":-37.143446,"marketCap":2893227437},{"date":"2022-02-18","current":-27.106738,"twenty":-59.724487,"median":-43.492185,"eighty":-36.968378,"marketCap":2729865412},{"date":"2022-02-25","current":-28.071482,"twenty":-59.678646,"median":-43.437917,"eighty":-36.905651,"marketCap":2827022827},{"date":"2022-03-04","current":-25.322389,"twenty":-59.583656,"median":-43.360924,"eighty":-36.834452,"marketCap":2550167185},{"date":"2022-03-11","current":-22.70136,"twenty":-59.306192,"median":-43.319423,"eighty":-36.766338,"marketCap":2286208545},{"date":"2022-03-18","current":-28.291592,"twenty":-59.172166,"median":-43.295217,"eighty":-36.444632,"marketCap":3040073042},{"date":"2022-03-25","current":-28.785804,"twenty":-59.048339,"median":-43.241759,"eighty":-36.064649,"marketCap":3093178556},{"date":"2022-04-01","current":-27.724464,"twenty":-59.048339,"median":-43.1764,"eighty":-35.678665,"marketCap":2979132288},{"date":"2022-04-08","current":-25.415442,"twenty":-58.958192,"median":-43.086807,"eighty":-35.293402,"marketCap":2731016361},{"date":"2022-04-14","current":-26.428171,"twenty":-58.866018,"median":-43.039133,"eighty":-34.945236,"marketCap":2839839136},{"date":"2022-04-22","current":-23.843687,"twenty":-58.778063,"median":-42.940117,"eighty":-34.48789,"marketCap":2562123414},{"date":"2022-04-29","current":-23.14693,"twenty":-58.704534,"median":-42.888728,"eighty":-33.407653,"marketCap":2487253345},{"date":"2022-05-06","current":-21.039181,"twenty":-58.614907,"median":-42.82356,"eighty":-33.196501,"marketCap":2260765197},{"date":"2022-05-13","current":-21.537198,"twenty":-58.533862,"median":-42.744231,"eighty":-33.138326,"marketCap":2314279623},{"date":"2022-05-20","current":-19.528801,"twenty":-58.506847,"median":-42.67719,"eighty":-32.784627,"marketCap":2098467346},{"date":"2022-05-27","current":-21.055509,"twenty":-58.47232,"median":-42.506172,"eighty":-32.56425,"marketCap":2262519768},{"date":"2022-06-03","current":-19.41561,"twenty":-58.365647,"median":-42.492303,"eighty":-32.253988,"marketCap":2285547362},{"date":"2022-06-10","current":-18.661968,"twenty":-58.119439,"median":-42.449993,"eighty":-31.627913,"marketCap":2196830881},{"date":"2022-06-17","current":-17.871017,"twenty":-57.794408,"median":-42.412967,"eighty":-30.853018,"marketCap":2103722495},{"date":"2022-06-24","current":-21.251213,"twenty":-57.545961,"median":-42.37641,"eighty":-30.527663,"marketCap":2501629088},{"date":"2022-07-01","current":-18.975364,"twenty":-57.27835,"median":-42.328632,"eighty":-30.205871,"marketCap":2233722883},{"date":"2022-07-08","current":-20.758734,"twenty":-57.119373,"median":-42.300639,"eighty":-29.937792,"marketCap":2443655942},{"date":"2022-07-15","current":-19.512613,"twenty":-57.022546,"median":-42.274674,"eighty":-29.686169,"marketCap":2296966315},{"date":"2022-07-22","current":-19.751391,"twenty":-56.538634,"median":-42.258991,"eighty":-29.576542,"marketCap":2325074507},{"date":"2022-07-29","current":-19.348454,"twenty":-55.37095,"median":-42.1379,"eighty":-29.489533,"marketCap":2277641933},{"date":"2022-08-05","current":-21.340755,"twenty":-54.581356,"median":-41.999461,"eighty":-29.249821,"marketCap":2512169660},{"date":"2022-08-12","current":-21.370602,"twenty":-54.282209,"median":-41.907002,"eighty":-28.899625,"marketCap":2515683184},{"date":"2022-08-19","current":-19.214141,"twenty":-54.164004,"median":-41.742363,"eighty":-28.761236,"marketCap":2261831075},{"date":"2022-08-26","current":-19.318607,"twenty":-54.013801,"median":-41.687142,"eighty":-28.490216,"marketCap":2274128409},{"date":"2022-09-02","current":-16.562766,"twenty":-53.825684,"median":-41.612639,"eighty":-28.401837,"marketCap":2096100841},{"date":"2022-09-09","current":-17.753369,"twenty":-53.67791,"median":-41.5952,"eighty":-28.368118,"marketCap":2246777593},{"date":"2022-09-16","current":-16.597991,"twenty":-53.584381,"median":-41.569297,"eighty":-28.257217,"marketCap":2100558733},{"date":"2022-09-23","current":-15.858267,"twenty":-53.533149,"median":-41.530643,"eighty":-28.105632,"marketCap":2006943000},{"date":"2022-09-30","current":-16.252786,"twenty":-53.345477,"median":-41.466004,"eighty":-27.873415,"marketCap":2056871391},{"date":"2022-10-07","current":-16.182337,"twenty":-53.110426,"median":-41.390601,"eighty":-27.717262,"marketCap":2047955607},{"date":"2022-10-14","current":-14.646529,"twenty":-52.79331,"median":-41.34773,"eighty":-27.636067,"marketCap":1853591514},{"date":"2022-10-21","current":-16.485271,"twenty":-52.578578,"median":-41.307589,"eighty":-27.328715,"marketCap":2086293479},{"date":"2022-10-28","current":-17.922449,"twenty":-52.484531,"median":-41.281723,"eighty":-27.012825,"marketCap":2268175475},{"date":"2022-11-04","current":-14.604259,"twenty":-52.445692,"median":-41.223096,"eighty":-26.683037,"marketCap":1848242043},{"date":"2022-11-11","current":-17.35885,"twenty":-52.440537,"median":-41.165581,"eighty":-26.46868,"marketCap":2196849202},{"date":"2022-11-18","current":-15.442613,"twenty":-51.97825,"median":-41.046215,"eighty":-26.415612,"marketCap":1954339874},{"date":"2022-11-25","current":-15.379208,"twenty":-51.971496,"median":-40.952393,"eighty":-26.24103,"marketCap":1946315669},{"date":"2022-12-02","current":-16.042428,"twenty":-51.941247,"median":-40.886211,"eighty":-26.002015,"marketCap":2129728606},{"date":"2022-12-09","current":-16.110204,"twenty":-51.872986,"median":-40.837833,"eighty":-25.713912,"marketCap":2138726192},{"date":"2022-12-16","current":-18.028246,"twenty":-51.7604,"median":-40.772608,"eighty":-25.598799,"marketCap":2393357876},{"date":"2022-12-23","current":-17.994359,"twenty":-51.70784,"median":-40.745253,"eighty":-25.338499,"marketCap":2388859083},{"date":"2022-12-30","current":-18.001136,"twenty":-51.570726,"median":-40.701201,"eighty":-25.184081,"marketCap":2389758841},{"date":"2023-01-06","current":-16.049206,"twenty":-51.363479,"median":-40.623172,"eighty":-24.85486,"marketCap":2130628364},{"date":"2023-01-13","current":-18.78733,"twenty":-51.102161,"median":-40.574619,"eighty":-24.231092,"marketCap":2494130839},{"date":"2023-01-20","current":-18.882216,"twenty":-50.978262,"median":-40.523325,"eighty":-23.99114,"marketCap":2506727459},{"date":"2023-01-27","current":-19.925957,"twenty":-50.965686,"median":-40.469321,"eighty":-23.312385,"marketCap":2645290284},{"date":"2023-02-03","current":-21.220466,"twenty":-50.951221,"median":-40.311267,"eighty":-22.57339,"marketCap":2817144176},{"date":"2023-02-10","current":-19.627745,"twenty":-50.890949,"median":-40.250171,"eighty":-21.596594,"marketCap":2605700905},{"date":"2023-02-17","current":-20.664708,"twenty":-50.876484,"median":-40.190227,"eighty":-21.430411,"marketCap":2743363971},{"date":"2023-02-24","current":-19.485417,"twenty":-50.857197,"median":-40.120759,"eighty":-21.251213,"marketCap":2586805975},{"date":"2023-03-03","current":-20.834146,"twenty":-50.688437,"median":-40.045986,"eighty":-21.055509,"marketCap":2765857936},{"date":"2023-03-10","current":-18.204462,"twenty":-50.646894,"median":-39.953806,"eighty":-20.967665,"marketCap":2416751599},{"date":"2023-03-17","current":-22.814647,"twenty":-50.628165,"median":-39.81605,"eighty":-20.881589,"marketCap":2929925462},{"date":"2023-03-24","current":-22.508745,"twenty":-50.547877,"median":-39.758269,"eighty":-20.937818,"marketCap":2890640524},{"date":"2023-03-31","current":-24.884826,"twenty":-50.538628,"median":-39.648544,"eighty":-20.967665,"marketCap":3195783993},{"date":"2023-04-06","current":-22.608341,"twenty":-50.398102,"median":-39.410762,"eighty":-20.985573,"marketCap":2903430969},{"date":"2023-04-14","current":-23.753697,"twenty":-50.260054,"median":-39.321908,"eighty":-21.029355,"marketCap":3050521084},{"date":"2023-04-21","current":-24.273021,"twenty":-50.211876,"median":-39.198908,"eighty":-21.041663,"marketCap":3117214118},{"date":"2023-04-28","current":-22.053448,"twenty":-50.10983,"median":-39.086878,"eighty":-21.052864,"marketCap":2832169920},{"date":"2023-05-05","current":-20.085339,"twenty":-50.030853,"median":-39.045525,"eighty":-21.029355,"marketCap":2579419472},{"date":"2023-05-12","current":-21.254175,"twenty":-50.011348,"median":-38.97946,"eighty":-20.981096,"marketCap":2729524925},{"date":"2023-05-19","current":-21.074906,"twenty":-49.936988,"median":-38.858126,"eighty":-20.935287,"marketCap":2706502616},{"date":"2023-05-26","current":-18.98821,"twenty":-49.739821,"median":-38.781427,"eighty":-20.865452,"marketCap":2438522942},{"date":"2023-06-02","current":-23.7011,"twenty":-49.634889,"median":-38.748697,"eighty":-20.83367,"marketCap":2555476271},{"date":"2023-06-09","current":-19.16437,"twenty":-49.587066,"median":-38.685442,"eighty":-20.780404,"marketCap":2066321490},{"date":"2023-06-16","current":-19.591955,"twenty":-49.518553,"median":-38.668128,"eighty":-20.758997,"marketCap":2112424156},{"date":"2023-06-23","current":-18.642716,"twenty":-49.490829,"median":-38.652026,"eighty":-20.740419,"marketCap":2010076237},{"date":"2023-06-30","current":-18.830853,"twenty":-49.425691,"median":-38.650282,"eighty":-20.728887,"marketCap":2030361410},{"date":"2023-07-07","current":-18.753888,"twenty":-49.321753,"median":-38.534252,"eighty":-20.640309,"marketCap":2022062930},{"date":"2023-07-14","current":-21.12271,"twenty":-49.135663,"median":-38.486364,"eighty":-20.586625,"marketCap":2277471700},{"date":"2023-07-21","current":-20.626711,"twenty":-49.077653,"median":-38.375503,"eighty":-20.595005,"marketCap":2223992607},{"date":"2023-07-28","current":-21.105606,"twenty":-49.061015,"median":-38.330676,"eighty":-20.595005,"marketCap":2275627593},{"date":"2023-08-04","current":-20.883262,"twenty":-49.007339,"median":-38.158206,"eighty":-20.613914,"marketCap":2251654207},{"date":"2023-08-11","current":-20.549746,"twenty":-48.954208,"median":-37.988814,"eighty":-20.586625,"marketCap":2215694127},{"date":"2023-08-18","current":-20.01954,"twenty":-48.941266,"median":-37.845067,"eighty":-20.541194,"marketCap":2158526822},{"date":"2023-08-25","current":-20.66947,"twenty":-48.894876,"median":-37.770349,"eighty":-20.506987,"marketCap":2228602874},{"date":"2023-09-01","current":-25.511357,"twenty":-48.832826,"median":-37.755599,"eighty":-20.541194,"marketCap":2375209352},{"date":"2023-09-07","current":-24.043412,"twenty":-48.807682,"median":-37.686377,"eighty":-20.560008,"marketCap":2238537799},{"date":"2023-09-14","current":-23.412009,"twenty":-48.750972,"median":-37.671633,"eighty":-20.577111,"marketCap":2179751687},{"date":"2023-09-22","current":-22.590183,"twenty":-48.595885,"median":-37.578261,"eighty":-20.58462,"marketCap":2103236431},{"date":"2023-09-28","current":-22.048981,"twenty":-48.583225,"median":-37.547623,"eighty":-20.587293,"marketCap":2052848336},{"date":"2023-10-05","current":-21.978825,"twenty":-48.576545,"median":-37.531928,"eighty":-20.595005,"marketCap":2046316545},{"date":"2023-10-11","current":-21.497757,"twenty":-48.562801,"median":-37.500901,"eighty":-20.605423,"marketCap":2001527127},{"date":"2023-10-20","current":-20.345196,"twenty":-48.534663,"median":-37.448341,"eighty":-20.589221,"marketCap":1894219146},{"date":"2023-10-27","current":-19.894194,"twenty":-48.514606,"median":-37.410785,"eighty":-20.580532,"marketCap":1852229066},{"date":"2023-11-03","current":-20.485508,"twenty":-48.433814,"median":-37.299311,"eighty":-20.506205,"marketCap":1907282726},{"date":"2023-11-10","current":-20.746087,"twenty":-48.370598,"median":-37.219715,"eighty":-20.506987,"marketCap":1931543661},{"date":"2023-11-17","current":-21.217133,"twenty":-48.32991,"median":-37.120374,"eighty":-20.524091,"marketCap":1975399966},{"date":"2023-11-24","current":-21.858558,"twenty":-48.320008,"median":-37.057747,"eighty":-20.549746,"marketCap":2035119191},{"date":"2023-11-30","current":-22.048981,"twenty":-48.252059,"median":-36.968279,"eighty":-20.57027,"marketCap":2052848336},{"date":"2023-12-07","current":-26.625426,"twenty":-48.121131,"median":-36.925787,"eighty":-20.578821,"marketCap":2015198621},{"date":"2023-12-15","current":-28.276615,"twenty":-48.00719,"median":-36.911135,"eighty":-20.582242,"marketCap":2140172179},{"date":"2024-01-05","current":-26.103359,"twenty":-47.918569,"median":-36.904212,"eighty":-20.585288,"marketCap":1975684923},{"date":"2024-01-12","current":-31.117632,"twenty":-47.865829,"median":-36.842529,"eighty":-20.591149,"marketCap":2355200212},{"date":"2024-01-19","current":-31.627558,"twenty":-47.844972,"median":-36.829603,"eighty":-20.601178,"marketCap":2393794988},{"date":"2024-01-26","current":-29.053645,"twenty":-47.78321,"median":-36.766338,"eighty":-20.619869,"marketCap":2198983265},{"date":"2024-02-02","current":-29.32075,"twenty":-47.731847,"median":-36.504107,"eighty":-20.628421,"marketCap":2219199576},{"date":"2024-02-09","current":-29.393596,"twenty":-47.672575,"median":-36.388531,"eighty":-20.635263,"marketCap":2224713115},{"date":"2024-02-16","current":-29.733547,"twenty":-47.618326,"median":-36.095963,"eighty":-20.635379,"marketCap":2250442965},{"date":"2024-02-23","current":-28.10664,"twenty":-47.602066,"median":-35.89466,"eighty":-20.635842,"marketCap":2127307254},{"date":"2024-03-01","current":-29.332891,"twenty":-47.570415,"median":-35.678665,"eighty":-20.651153,"marketCap":2220118499},{"date":"2024-03-08","current":-29.55143,"twenty":-47.518149,"median":-35.35785,"eighty":-20.660918,"marketCap":2236659117},{"date":"2024-03-15","current":-26.009561,"twenty":-47.49129,"median":-35.24315,"eighty":-20.664708,"marketCap":2126463652},{"date":"2024-03-22","current":-25.786705,"twenty":-47.380514,"median":-34.925503,"eighty":-20.66947,"marketCap":2108243640},{"date":"2024-03-28","current":-24.935846,"twenty":-47.342533,"median":-34.589879,"eighty":-20.66947,"marketCap":2038679948},{"date":"2024-04-05","current":-25.071983,"twenty":-47.312176,"median":-34.414946,"eighty":-20.689994,"marketCap":2049810139},{"date":"2024-04-12","current":-25.888808,"twenty":-47.269427,"median":-33.423363,"eighty":-20.697474,"marketCap":2116591283},{"date":"2024-04-19","current":-23.631195,"twenty":-47.158961,"median":-33.184171,"eighty":-20.697474,"marketCap":1932015619},{"date":"2024-04-26","current":-22.916473,"twenty":-46.951231,"median":-33.003753,"eighty":-20.698257,"marketCap":1873582118},{"date":"2024-05-03","current":-23.897861,"twenty":-46.656905,"median":-32.649248,"eighty":-20.698257,"marketCap":1953817432},{"date":"2024-05-10","current":-23.114516,"twenty":-46.598159,"median":-32.247909,"eighty":-20.698257,"marketCap":1889773514},{"date":"2024-05-17","current":-24.517522,"twenty":-46.43348,"median":-31.759443,"eighty":-20.698257,"marketCap":2004479038},{"date":"2024-05-24","current":-22.904066,"twenty":-46.181838,"median":-31.451512,"eighty":-20.698257,"marketCap":1872567685},{"date":"2024-05-31","current":-20.986625,"twenty":-46.068748,"median":-31.128449,"eighty":-20.698257,"marketCap":1715803469},{"date":"2024-06-07","current":-20.224161,"twenty":-45.830813,"median":-30.643949,"eighty":-20.66395,"marketCap":1892880316},{"date":"2024-06-14","current":-21.429439,"twenty":-45.725202,"median":-30.31849,"eighty":-20.645029,"marketCap":2005688335},{"date":"2024-06-21","current":-21.357939,"twenty":-45.671397,"median":-29.967092,"eighty":-20.641966,"marketCap":1998996334},{"date":"2024-06-28","current":-23.247571,"twenty":-45.51108,"median":-29.932669,"eighty":-20.635726,"marketCap":2175856364},{"date":"2024-07-05","current":-22.542789,"twenty":-45.42729,"median":-29.794252,"eighty":-20.635726,"marketCap":2109892353},{"date":"2024-07-12","current":-21.439653,"twenty":-45.27192,"median":-29.668005,"eighty":-20.635726,"marketCap":2006644335},{"date":"2024-07-15","current":-21.807365,"twenty":-45.165128,"median":-29.6527,"eighty":-20.635726,"marketCap":2041060341},{"date":"2024-08-02","current":-20.438659,"twenty":-44.67116,"median":-29.473821,"eighty":-20.619869,"marketCap":1912956320},{"date":"2024-08-09","current":-18.937169,"twenty":-44.592228,"median":-29.326821,"eighty":-20.554877,"marketCap":1772424296},{"date":"2024-08-16","current":-19.846234,"twenty":-44.342086,"median":-29.065787,"eighty":-20.488395,"marketCap":1857508310},{"date":"2024-08-23","current":-19.366166,"twenty":-44.293477,"median":-28.968658,"eighty":-20.439367,"marketCap":1812576303},{"date":"2024-08-30","current":-20.193518,"twenty":-44.126836,"median":-28.878841,"eighty":-20.396729,"marketCap":1890012316},{"date":"2024-09-06","current":-20.851386,"twenty":-44.070828,"median":-28.815003,"eighty":-20.350301,"marketCap":1731811836},{"date":"2024-09-13","current":-19.495653,"twenty":-43.902513,"median":-28.750118,"eighty":-20.261779,"marketCap":1619211496},{"date":"2024-09-20","current":-20.358392,"twenty":-43.724824,"median":-28.493474,"eighty":-20.244564,"marketCap":1690866258},{"date":"2024-09-27","current":-20.324779,"twenty":-43.52784,"median":-28.425739,"eighty":-20.226358,"marketCap":1688074514},{"date":"2024-10-04","current":-19.753355,"twenty":-43.367535,"median":-28.373476,"eighty":-20.209123,"marketCap":1640614867},{"date":"2024-10-11","current":-20.30237,"twenty":-43.311657,"median":-28.264591,"eighty":-20.195561,"marketCap":1686213351},{"date":"2024-10-18","current":-21.030656,"twenty":-43.248031,"median":-28.136018,"eighty":-20.195561,"marketCap":1746701137},{"date":"2024-10-25","current":-20.078282,"twenty":-43.248031,"median":-28.049113,"eighty":-20.145499,"marketCap":1667601725},{"date":"2024-10-31","current":-20.649706,"twenty":-43.248031,"median":-27.765641,"eighty":-20.132647,"marketCap":1715061372},{"date":"2024-11-08","current":-22.688907,"twenty":-43.252213,"median":-27.636067,"eighty":-20.132233,"marketCap":1884427173},{"date":"2024-11-15","current":-21.960621,"twenty":-43.252213,"median":-27.448241,"eighty":-20.132233,"marketCap":1823939387},{"date":"2024-11-22","current":-22.229527,"twenty":-43.231304,"median":-27.106738,"eighty":-20.132233,"marketCap":1846273338},{"date":"2024-11-29","current":-25.707412,"twenty":-43.145724,"median":-26.876224,"eighty":-20.132233,"marketCap":1914893729},{"date":"2024-12-06","current":-25.40483,"twenty":-43.145724,"median":-26.625426,"eighty":-20.132233,"marketCap":1892354961},{"date":"2024-12-13","current":-24.521289,"twenty":-43.145724,"median":-26.466422,"eighty":-20.132233,"marketCap":1826541758},{"date":"2024-12-20","current":-22.572657,"twenty":-43.145724,"median":-26.327469,"eighty":-20.132233,"marketCap":1681392092},{"date":"2024-12-27","current":-22.173248,"twenty":-43.145724,"median":-26.203648,"eighty":-20.132233,"marketCap":1651640919},{"date":"2025-01-03","current":-21.785943,"twenty":-43.145724,"median":-26.12294,"eighty":-20.132233,"marketCap":1622791296},{"date":"2025-01-10","current":-21.434947,"twenty":-43.151859,"median":-25.994723,"eighty":-20.130744,"marketCap":1596646325},{"date":"2025-01-17","current":-22.584761,"twenty":-43.151859,"median":-25.832017,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-24","current":-22.584761,"twenty":-43.151859,"median":-25.722549,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-31","current":-22.330591,"twenty":-43.151859,"median":-25.688138,"eighty":-20.130744,"marketCap":1663361078},{"date":"2025-02-07","current":-23.032583,"twenty":-43.151859,"median":-25.544418,"eighty":-20.130744,"marketCap":1715651020},{"date":"2025-02-14","current":-23.601438,"twenty":-43.151859,"median":-25.410136,"eighty":-20.130744,"marketCap":1758023904},{"date":"2025-02-21","current":-22.149042,"twenty":-43.151859,"median":-25.353801,"eighty":-20.130744,"marketCap":1649837817},{"date":"2025-02-28","current":-21.229191,"twenty":-43.151859,"median":-25.248903,"eighty":-20.130744,"marketCap":1581319962},{"date":"2025-03-07","current":-20.902402,"twenty":-43.157994,"median":-25.114351,"eighty":-20.129255,"marketCap":1556978093},{"date":"2025-03-14","current":-25.841364,"twenty":-43.157994,"median":-25.015259,"eighty":-20.118618,"marketCap":1407320673},{"date":"2025-03-21","current":-31.526661,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1716941957},{"date":"2025-03-28","current":-31.810986,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1732426315},{"date":"2025-04-02","current":-30.740585,"twenty":-43.157994,"median":-25.114351,"eighty":-20.118618,"marketCap":1674132264}],"updateTime":1743724858128}}}